Author | Cheryl Guttman Krader, BS, Pharm


Erythropoietin offers hope as retinal neuroprotective agent

July 28, 2020


Investigators find treatment with EPO shows no effect on the development of ROP.

Surgeons discuss MIPS, impact of pass-through medications

July 03, 2020


Bonuses are the norm and not risked by pass-through medication use

Shaffer Prize report goes down one path, but leads to another

February 09, 2018


Research aiming to elucidate the underlying factors for oxidative damage to the trabecular meshwork in glaucoma has led to studies of alterations in gene expression that may ultimately guide the development of genetic therapy for glaucoma, said Carla J. Siegfried, MD, recipient of the 2018 Shaffer Prize for Innovative Glaucoma Research.